Eikon Therapeutics, Inc. Common Stock (EIKN) Stock Score, Valuation & Financial Research

Eikon Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EIKN

Eikon Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 8.04. These figures are a research snapshot, not a buy or sell recommendation.

What Eikon Therapeutics, Inc. Common Stock does

Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Eikon Therapeutics is a clinical-stage biopharmaceutical company that generates value by developing a pipeline of novel oncology therapies. The company utilizes a proprietary single-molecule tracking technology platform to discover internally-derived drug candidates while also in-licensing promising assets from third parties to address unmet medical needs.

Products and services

  • The company is developing a pipeline of oncology drug candidates, including EIK1001, a TLR 7 and 8 agonist currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer.

Business relationships and partnerships

  • Seven and Eight and SW — The company holds a worldwide, exclusive license from these entities for certain patents and intellectual property rights to develop and commercialize TLR 7 and 8 agonist product candidates, including EIK1001. Source

Business strengths to evaluate

  • Proprietary single-molecule tracking technology platform Source
  • Experienced management team with expertise in in-licensing assets Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of clinical-stage product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EIKN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.04
Market capitalization:
435.27M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -322.16M
Free cash flow:
USD -235.26M
Cash:
USD 143.01M
Total debt:
USD 252.22M
EPS:
USD -4.63

What stands out

  • Free cash flow is USD -235.26M, negative for the stored period.
  • The balance sheet shows USD 143.01M of cash versus USD 252.22M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 109.21M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EIKN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EIKN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does EIKN's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for EIKN to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of EIKN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research EIKN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.